Loading...
The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani
BACKGROUND: New drugs are needed for leishmaniasis because current treatments such as pentavalent antimonials are toxic and require prolonged administration, leading to poor patient compliance. Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/Th2 responses and has the potentia...
Na minha lista:
| Udgivet i: | J Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784510/ https://ncbi.nlm.nih.gov/pubmed/30239895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy552 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|